Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Postsurgical Pain and Opioid Use in Older Adults: Effects of Mild Cognitive Impairment

NCT07885085 is registered in ClinicalTrials.gov with Miklos Kertai as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07885085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Postsurgical Pain and Opioid Use in Older Adults: Effects of Mild Cognitive Impairment
Lead sponsor
Miklos Kertai
Phase
Observational
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
January 31, 2032
Enrollment
552 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive dysfunction, mild cognitive impairment (mci), opioid use, postoperative pain

Arms

As registered; 3 arms.

  • Older Adults with Mild Cognitive Impairment

    Older adults aged 65 years or older undergoing elective major orthopedic or complex spine surgery who meet protocol-defined psychometric criteria for mild cognitive impairment. Follow-up includes cognitive, pain, quantitative sensory testing, heart rate variability, biomarker, and opioid use assessments.

  • Cognitively Intact Older Adults

    Older adults aged 65 years or older undergoing elective major orthopedic or complex spine surgery who do not meet criteria for mild cognitive impairment. Participants undergo the same longitudinal assessments as the MCI cohort.

  • Caregiver Participants

    Adult informal caregivers of enrolled patient participants. Caregivers may serve as spouses/partners, adult family members, or other unpaid caregivers. Caregiver participants complete questionnaires regarding observations of patient pain, recovery, medication management, and home opioid use during postoperative follow-up. Caregiver enrollment is voluntary and independent of patient enrollment except when a caregiver serves as a surrogate/LAR for consent purposes.

Primary endpoints

Registered primary outcome measures; 4 primary.

  • Past 24-Hour Average Pain Intensity Baseline, 2 weeks, 1 month, 3 months, and 6 months after surgery.

    Average postoperative pain intensity will be measured using an 11-point Numeric Rating Scale (NRS) ranging from 0 (No Pain) to 10 (Worst Possible Pain). Participants will rate their average pain during the previous 24 hours at each assessment. Results will be reported as the mean NRS score and standard deviation for each study group at each time point, as well as the mean change from baseline. Between-group differences in pain trajectories across the postoperative period will be assessed.

  • Cumulative Postoperative Opioid Use Postoperative Discharge through 6 months after surgery.

    Postoperative opioid use will be quantified through pill counts and electronic health record review. All opioid medications consumed will be converted to morphine milligram equivalents (MME). Results will be reported as the cumulative MME consumed during each follow-up interval and cumulatively through 6 months after surgery. Mean MME, standard deviation, median, and range will be reported for each study group.

  • Heat Pain Threshold Temperature Baseline, 2 weeks, 1 month, 3 months, and 6 months after surgery.

    Heat pain threshold will be assessed using the Medoc TSA2 Air quantitative sensory testing system. The outcome measure is the average temperature in degrees Celsius at which thermal stimulation is first perceived as painful across four testing trials. Results will be reported as mean threshold temperature (°C), standard deviation, and mean change from baseline. Lower temperatures indicate increased pain sensitivity.

  • High-Frequency Heart Rate Variability (HF-HRV) Baseline, 2 weeks, 1 month, 3 months, and 6 months after surgery.

    Cardiac vagal regulation will be assessed from a 5-minute resting electrocardiographic recording. The primary outcome will be high-frequency heart rate variability derived using Kubios HRV software according to established HRV analysis methods. Results will be reported as mean HF-HRV values and mean change from baseline for each study group. Higher values indicate greater vagal inhibitory control.

Papers

PubMed papers this trial cites; 3 papers, results papers first, then newest first.

Source: PubMed, NCBI/NLM (public domain).

Similar trials

Same condition (Plaque, Amyloid) and phase, most recent start first.